Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1 by Marso, SP et al.
Trial DesignDesign of DEVOTE (Trial Comparing
Cardiovascular Safety of Insulin Degludec vs
Insulin Glargine in Patients With Type 2
Diabetes atHigh Risk of Cardiovascular Events)
– DEVOTE 1
Steven P. Marso, MD, a Darren K. McGuire, MD,MHSc, a Bernard Zinman, MD, FRCPC, FACP, b Neil R. Poulter, FMedSci, c
Scott S. Emerson,MD,PhD,d ThomasR.Pieber,MD,eRichardE.Pratley,MD,f Poul-MartinHaahr,MD,gMartinLange,MD,PhD,g
KirstineBrownFrandsen,MD, g RasmusRabøl,MD, PhD, g and JohnB.Buse,MD, PhDhDallas, TX; ON, Canada; London,
UK; Seattle, WA; Graz, Austria; Orlando, FL; Søborg, Denmark; and Chapel Hill, NCDEVOTE was designed to evaluate the cardiovascular safety of insulin degludec (IDeg) vs insulin glargine U100 (IGlar)
in patients with T2D at high risk of cardiovascular events. DEVOTE is a phase 3b, multicenter, international, randomized,
double-blind, active comparator-controlled trial, designed as an event-driven trial that would continue until 633 positively
adjudicated primary events were accrued. The primary end point was the time from randomization to a composite outcome
consisting of the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Patients with T2D
at high risk of cardiovascular complications were randomized 1:1 to receive either IDeg or IGlar, each added to background
therapies. This trial was designed to demonstrate statistical noninferiority of IDeg vs IGlar for the primary end point. DEVOTE
enrolled 7,637 patients between October 2013 and November 2014 at 436 sites in 20 countries. Of these, 6,506 patients
had prior cardiovascular disease or chronic kidney disease, and the remainder had multiple cardiovascular risk factors.
DEVOTE was designed to provide conclusive evidence regarding the cardiovascular safety of IDeg relative to IGlar in a high-
risk population of patients with T2D. (Am Heart J 2016;179:175-83.)Background
Current treatment guidelines for type 2 diabetes (T2D)
highlight the importance of patient-centered engagement
and supportwith lifestyle interventions and pharmacologic
therapies to manage hyperglycemia to individualized
glycemic targets.1 Although there are now 12 classes of
antihyperglycemic therapies available for the treatment of
T2D, many patients do not achieve adequate glycemic
control even with combination therapies. The use of basal
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.treatment strategy for those failing to achieve glycemic
targets in the absence of insulin therapy.1 Although insulin
is effective at lowering circulating glucose levels, it has a
narrow therapeutic window and can be associated with
hypoglycemia and weight gain. As a result, providers often
underutilize, underdose, or delay insulin initiation until late
in the course of diabetes. Basal insulin with improved
pharmacokinetics and pharmacodynamics could potentially
mitigate these risks—particularly nocturnal hypoglycemia.
Insulin degludec (IDeg) is a long-acting basal insulin analog
that is administered once daily and is presently approved for
the treatment of T2D. At the time of filing the US Food and
Drug Administration (FDA) new drug application, the
cardiovascular safety and efficacy of IDeg was evaluated in
8,959 patients, as a part of the IDeg development program.
The primary cardiovascular safety end point was a
meta-analysis using a prespecified, prospectively adjudicat-
ed, 4-component composite outcome of major adverse
cardiovascular events (MACE; cardiovascular death, nonfatal
myocardial infarction, nonfatal stroke, and unstable angina
requiring hospitalization). Across the individual trials, there
was no consistent pattern in the incidence rates or estimated
hazard ratios (HRs). Overall, the incidence rates for MACE
were 1.48 and 1.44 per 100 patient-years of exposure for the
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parator groups, respectively; HR 1.097 (95% CI,
0.681-1.768).2 A sensitivity analysis using a 3-component
MACE (cardiovascular death, myocardial infarction, and
stroke) was requested by the FDA. When hospitalized
unstable anginawas excluded, the total number of patients
with a MACE fell from 80 to 54, and the HR associated with
IDeg use for this reduced end point was 1.39 (95% CI,
0.76-2.57), representing a wider CI and an increased HR.
Given these data, the FDA mandated a dedicated cardiovas-
cular outcomes trial to assess the cardiovascular safety of
IDeg compared with insulin glargine U100 (IGlar).
The objective of DEVOTE was to compare the
cardiovascular safety of IDeg with IGlar, each added to
standard of care, in an at-risk cardiovascular population.
Trial design
DEVOTE is a phase 3b, multicenter, international,
randomized, double-blind, active comparator-controlled
cardiovascular outcomes trial, designed as an event-driven
trial that would continue until at least 633 positively
adjudicated, primary cardiovascular outcome events were
accrued. The primary end point was the time from
randomization to the first event of a composite MACE
outcome consisting of cardiovascular death, nonfatal
myocardial infarction, or nonfatal stroke. Patients with
T2D at high risk of cardiovascular events were randomized
1:1 to receive either IDeg or IGlar, each added to standard of
care. An interim analysis was performed to assess the
noninferiority of IDeg to IGlar for the primary end point after
150 primary events were accrued to support the resubmis-
sion of the new drug application for IDeg to the FDA. The
final noninferiority analysis will be assessed at trial
completion after at least 633 adjudication-confirmedprimary
MACE events have accrued. This trial is registered with
ClinicalTrials.gov number NCT01959529. The trial was
conducted in accordance with the Declaration of Helsinki3
and Good Clinical Practice Guidelines.4 The protocol was
approved by independent ethics committees or institutional
review boards before the start of the trial. Signed informed
consent was obtained from each patient before any
trial-related activities.
Funding
DEVOTE was funded by Novo Nordisk. The authors
drafted and edited this manuscript and are responsible for
its final contents. Submission support was provided by
Watermeadow Medical, an Ashfield company, part of
UDG Healthcare plc, funded by Novo Nordisk.Study population
Eligible patients included those with T2D treated with ≥1
oral or injectable antihyperglycemic therapy, a glycatedhemoglobin (HbA1c) ≥7.0% or HbA1c b7.0%, if treated
with ≥20 units/day of basal insulin. Two cohorts were
eligible for recruitment into the trial:
Prior cardiovascular disease (CVD) or history of
moderate chronic kidney disease (CKD) cohort: patients
were eligible if they were ≥50 years old and had a history of
CVDormoderateCKD.PriorCVDwasdefinedby any1of the
following: myocardial infarction; stroke or transient ischemic
attack (TIA); coronary, carotid, or peripheral revasculariza-
tion; N50% diameter stenosis found on angiography or other
imagingmodality of the coronary, carotid, or lower extremity
arteries; history of symptomatic coronary heart disease
documented by positive noninvasive stress test or unstable
angina pectoris with electrocardiogram (ECG) changes;
asymptomatic cardiac ischemia; New York Heart Association
(NYHA) class II to III congestive heart failure; or moderate
CKD (Stage 3) defined as estimated glomerular filtration rate
(eGFR) 30 to 59 mL/min per 1.73 m2 using the
CKD-Epidemiology Collaboration (CKD-EPI) equation.5
No prior CVD cohort: patients were eligible if they were
≥60 years old and did not have a history of CVDormoderate
CKD but did have at least one of the following: micro-
albuminuria or proteinuria; hypertension with left ventric-
ular hypertrophy; left ventricular systolic and diastolic
dysfunction as defined by the investigator; or an abnormal
ankle-brachial index of b0.9. The complete list of inclusion
and exclusion criteria is found in Table I.Randomized treatment regimen
After determining eligibility and obtaining written
informed consent, patients were randomized to receive
either IDeg or IGlar, both supplied by the trial sponsor
(Novo Nordisk) in identical 100-U/mL, 10-mL vials.
Commercially available IGlar (Lantus) vials were pro-
cured and the label removed. Identical empty vials and
vial covers were also procured and filled with IDeg.
Treatment was administered using 1-mL syringes. An
interactive voice/web response system was used for
randomization. The randomization code for a particular
patient could be broken in the case of a medical
emergency if knowing the treatment allocation would
influence the clinical management of the patient. All
patients continued their current pretrial antihyperglyce-
mic therapy with the exception of basal insulin, which
was discontinued. Patients self-administered the investi-
gational product subcutaneously once daily between
dinner and bedtime, starting on the day of randomization.
For patients who were taking rapid-acting insulin before
the trial, the investigator could decide on an individual
basis to replace this with insulin aspart, which was
provided free of charge by the trial sponsor. Premixed/
biphasic insulin products were replaced by the investi-
gational product according to treatment allocation, with
Table I. DEVOTE inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Type 2 diabetes An acute coronary or cerebrovascular event in the previous 60 d
HbA1c ≥7.0% or HbA1c b7.0% and current insulin treatment
corresponding to ≥20 U/d of basal insulin
Planned coronary, carotid or peripheral artery revascularization
Age ≥50 y at screening and at least 1 of the following conditions: Chronic heart failure NYHA class IV
• Prior myocardial infarction Current hemodialysis or peritoneal dialysis or
eGFR b30 mL/min per 1.73 m2 per CKD-EPI
• Prior stroke or prior TIA End-stage liver disease, defined as the presence
of acute or chronic liver disease and recent history
of 1 or more of the following: ascites, encephalopathy,
variceal bleeding, bilirubin ≥2.0 mg/dL,
albumin level ≤3.5 g/dL, prothrombin time ≥4 s
prolonged, international normalized ratio ≥1.7 or
prior liver transplant
• Prior coronary, carotid, or peripheral arterial revascularization Known or suspected hypersensitivity to trial products
or related products
• N50% stenosis on angiography or other imaging of coronary,
carotid, or lower-extremity artery
Female of child-bearing potential who is pregnant, breastfeeding
or intends to become pregnant, or is not using adequate
contraceptive methods as required by local law or practice
• History of symptomatic coronary heart disease documented
by positive exercise stress test or any cardiac imaging,
or unstable angina pectoris with ECG changes
Expected simultaneous participation in any other clinical
trial of an investigational medicinal product.
Participation in a clinical trial with stent(s) is allowed
• Asymptomatic cardiac ischemia documented by positive nuclear
imaging test or exercise test or dobutamine stress echocardiogram
Receipt of any investigational medicinal product
within 30 d before randomization
Brazil: receipt of any investigational medicinal product within 1 y
before randomization, unless there is a direct benefit to the patient
at the investigator's discretion
• Chronic heart failure NYHA class II-III Current or past (within the last 5 y) malignant neoplasms (except
basal cell and squamous cell skin carcinoma)
• Chronic kidney disease corresponding to glomerular
filtration rate 30-59 mL/min per 1.73m2 per CKD-EPI
Any condition that in the investigator's opinion would make the
patient unable to adhere to the initial trial visit schedule and
procedures
Age ≥60 y at screening and at least 1 of the following risk factors:
• Microalbuminuria or proteinuria
• Hypertension and left ventricular hypertrophy by ECG or imaging
• Left ventricular systolic and diastolic dysfunction by imaging
• Ankle/brachial index b0.9
CKD-EPI, Chronic Kidney Epidemiology Collaboration; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association; TIA, transient
ischemic attack.
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glycemic targets. There was no maximum insulin dose
prespecified. Intensification of therapy was determined
by the site investigator based upon clinical judgment.
The trial protocol provided an algorithm for basal insulin
titration to achieve a fasting self-measured blood glucose
(SMBG) of 71 to 90 mg/dL (4.0-5.0 mmol/L). Guidance on
adjustment of rapid-acting insulin was also provided,
aiming for premeal or bedtime SMBG values of 71 to 126
mg/dL (4.0-7.0 mmol/L). The trial leadership recognized
that this level of glycemic controlmay not be appropriate in
selected patients at higher cardiovascular risk, and that
investigators might reasonably recommend a less stringent
glycemic target. Therefore, an alternative fasting SMBG
target of 91 to 126 mg/dL (5.0-7.0 mmol/L) was also an
acceptable alternative target. The investigators were
required to prespecify the glycemic target for individual
patients before randomization. The option to reassess thisprespecified glycemic target was possible throughout the
trial duration. Titration adequacy was monitored centrally
and feedback provided to encourage adherence to the
protocol.Planned follow-up
After randomization, patients were seen weekly for 2
weeks, monthly for 6 months, and then every 3 months
for the remaining part of the trial. There was a planned
end-of-treatment follow-up visit 30 days after investiga-
tional product discontinuation. At every trial visit,
information regarding the use of concomitant medica-
tion, the occurrence of serious adverse events (AEs),
severe hypoglycemic events, and investigational product
compliance was obtained. After randomization, HbA1c
was measured at 7 days, 30 days, and then at every trial
visit thereafter.
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The primary end point was the time from randomiza-
tion to the first occurrence of a 3-component MACE
consisting of cardiovascular death, nonfatal myocardial
infarction, or nonfatal stroke. The key secondary end
point was severe hypoglycemia, defined according to
contemporary American Diabetes Association criteria, as
an episode requiring assistance from another person or
an episode temporally associated with an accident,
convulsion, or death.6 Other secondary end points
included the time from randomization to all-cause death,
the frequency of serious AEs, and the frequency of AEs
leading to discontinuation of the investigational product.
Additional end points were the change from baseline to the
final assessmentofHbA1c, fastingplasmaglucose,bloodpressure,
pulse rate, lipid profile, weight, body mass index, eGFR, as
well as basal and bolus insulin dose at the end of the trial.
Event adjudication
Acute coronary syndrome, cerebrovascular events, fatal
events, and severe hypoglycemic episodes were prospectively
adjudicated by an independent Event Adjudication Committee
(EAC).TheEACcomprised10experts incardiology,neurology,
and endocrinology. The EAC members were blinded to
treatment and were not involved in the design, conduct, or
reporting of the clinical trial results. The EAC had access to
relevant source documents and was empowered to request
additional clinical information from sites to resolve uncertainty
with event adjudication classification.
Identification of events for adjudication was performed
using several processes. The investigators classified all
documented AEs in the case report form as an acute
coronary syndrome (unstable angina or acute myocardial
infarction), a cerebrovascular event, a severe hypoglyce-
mic event, a fatal event, or none of the above. All events
except for “none of the above” triggered EAC adjudica-
tion. Further, AEs classified as “none of the above” were
systematically screened by blinded sponsor employees to
identify potentially missed events. Patients underwent a
12-lead ECG at baseline and at yearly intervals. All ECGs
were forwarded to a central core ECG lab for formal
reading. Any ECGs found to have changes suggestive of a
new myocardial infarction were sent for adjudication to
identify potentially silent myocardial infarctions. Lastly,
blinded sponsor employees reviewed preselected stan-
dardized queries using the Medical Dictionary for
Regulatory Activities (MedDRA) to identify events not
otherwise triggered for EAC adjudication.Nonfatal myocardial infarction
Acute coronary syndromewas triggered for EAC review if
the patient experienced symptoms of myocardial ischemia
that required hospitalization, periprocedural myocardial
ischemia, or if there was evidence of a silent myocardialinfarction. Both nonfatal myocardial infarctions and unsta-
ble angina requiring hospitalization underwent formal event
adjudication. The latterwas not a component of the primary
end point.
Stroke
Episodes of focal or global neurologic dysfunction
caused by the brain, spinal cord, or retinal vascular
injury as the result of hemorrhage or infarction were
triggers for event adjudication. All types of strokes
including ischemic, hemorrhagic, and undetermined
were adjudicated.
Fatal events
All fatal events were triggers for event adjudication. The
primary composite outcome included cardiovascular
mortality. Cardiovascular death included deaths that are
clearly cardiovascular and those that were undetermined
by EAC review.
Severe hypoglycemia
All hypoglycemic events reported as an episode
requiring the assistance of another person or fulfilling
the definition of a serious AE were triggers for event
adjudication. In addition, selected fatal events and events
identified via theMedDRA search of “accidents and injuries
(Standardized MedDRA Queries—narrow scope)” and
“convulsions (Standardized MedDRA Queries—road
scope)” were also triggers for adjudication.
Trial governance
DEVOTE was overseen by an executive Steering
Committee composed of 4 experts in endocrinology, 3
in cardiology, 1 in biostatistics, and 4 employees of the
trial sponsor (Novo Nordisk). The executive steering
committee independently oversaw all aspects of the trial.
The Global Expert Panel consisted of principal investiga-
tors from enrolling countries and designated employees
of the sponsor. This panel provided advice and active
implementation assistance for operational issues that
naturally arise during the execution of a global clinical
trial.
An independent external data monitoring committee
(IDMC) was established to perform ongoing safety
surveillance and data monitoring. The IDMC was
comprised of permanent members who were recognized
experts in the fields of cardiology, endocrinology,
neurology, and statistics. The IDMC had access to
complete, unblinded data and met at predetermined
intervals, as well as on an ad hoc basis, to evaluate all
relevant data and safety information that accumulated
during the course of the trial. The IDMC could recommend
terminating the trial prematurely. The IDMC also had
access to unblinded data for all planned and interim
data analyses.
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The sample size estimate was based on the number of
first MACE including cardiovascular death, nonfatal
myocardial infarction, or stroke occurring after random-
ization. The estimates were based on an intention-to-treat
principle and a log-rank test for a total of 633 first events.
This number of events would provide 91% power to
exclude an upper bound of a 95% CI exceeding 1.3 for
the primary analysis of noninferiority, assuming the true
HR was 1.0. To have a total of 633 first events with a trial
duration of approximately 5 years, 3,750 patients would
be needed for each randomized treatment arm with a 1:1
randomization scheme. This estimate was based on an
annual event rate projected to be 2.1 per 100
patient-years in both treatment groups, with an assumed
loss-to-follow-up rate of 1% per year throughout the trial.
The primary end point was the time from randomization
to the first positively adjudicated MACE, as determined by
the EAC.
Interim analyses
DEVOTE used an interim analysis to assess the
cardiovascular safety of IDeg using the data compiled
when a total of 150 positively adjudicated primary
end points were accrued. The interim analysis was
prespecified to establish the noninferiority of IDeg
relative to IGlar if the upper limit of the 2-sided 95% CI
for the HR (hazardIDeg/hazardIGlar) was b1.8.Final analysis of primary and secondary
end points
The primary end point will be presented descriptively
in a Kaplan-Meier plot according to randomized treat-
ment, and analyzed using a Cox proportional hazard
regression with treatment group as a factor using the full
analysis set (FAS). The FAS will be defined according to
the intention-to-treat principle. The HR and the corre-
sponding 2-sided 95% CI will be estimated. The analyses
done with the FAS will be considered confirmatory,
whereas the analyses done with the per-protocol set will
be considered supportive. The final noninferiority of
IDeg will be established at the trial completion if the
upper bound of the 95% CI is b1.3 and after the
accumulation of at least 633 primary events.
If noninferiority for the primary end point is estab-
lished, then the number of positively adjudicated severe
hypoglycemic episodes will be considered as secondary
confirmatory end points and analyzed using a
negative-binomial regression model with log-link func-
tion, and the logarithm of the duration of the exposure
time as offset. The model will include treatment group as
a fixed factor and fitted using the final analysis set.
Superiority will be considered confirmed if the upper limitof the 2-sided 95% CI for the ratio is b1.0. A hierarchical
testing strategywill be applied,meaning that therewill be no
penalty on the α level for the statistical test. Therewill be no
adjustment of the α level for the final statistical testing.
Data access management
The interim analysis was submitted in March 2015 by the
trial sponsor and used in the approval of IDeg by the FDA for
its use in the United States. The executive Steering
Committee, in collaboration with the sponsor, developed a
rigorous data accessmanagement plan tomitigate the risk of
performing an interim analysis on the overall integrity of the
clinical trial. This data access management plan tightly
restricted the numbers of individuals who had access to the
unblinded data and put in place very strict standards on how
these data were accessed, reviewed, shared with others,
analyzed, and stored to protect the overall integrity, blinding,
and confidentiality of DEVOTE. Three groups of individuals
had access to the unblinded data: (1) an external,
independent statistical team (Statistics Collaborative, Inc,
Washington, DC) with the sole responsibility of analyzing
the interim data; (2) a Novo Nordisk interim reporting team,
responsible for reviewing, interpreting, and creating the
clinical report to submit to the FDA; and (3) the IDMC. No
other individuals, including the DEVOTE Steering Commit-
tee and Novo Nordisk employees (including the Novo
Nordisk executive management and internal safety commit-
tee), had access to these unblinded interim data.
The number of individuals in the Novo Nordisk interim
reporting team was limited and each person had a vital
role in the group. This team was granted sole authority to
decide whether or not to submit the interim analyses
results to the FDA. They were solely responsible for
generating the report of the interim data for the FDA
submission and all communication with the FDA
regarding the interim data or additional data requests.
These individuals signed a strict nondisclosure agree-
ment, were identified prospectively, and were physically
separated—with separate security access—from other
employees of Novo Nordisk. The interim reporting team
received formal training regarding the importance of
keeping interim data confidential and they worked on a
secured network separate from the NovoNordisk network. A
separate and secure IT infrastructurewas created for handling
the unblinded data within Novo Nordisk and an institutional
firewall was established to support these functions.Study population
DEVOTE enrolled 7,637 patients (n = 6,506 in the
“prior CVD/CKD” cohort; n = 1,131 in the “no prior
CVD” cohort) between October 2013 and November
2014 at 436 sites in 20 countries. A total of 8,205 patients
were screened, of whom 561 were ineligible, primarily as
a result of not meeting HbA1c criteria (26%), not meeting







Age (y) 64.8 ± 7.7 66.2 ± 5.3 65.0 ± 7.4
Men 4179 (64.2) 599 (53.0) 4778 (62.6)
Ethnicity
Hispanic or Latino 893 (13.7) 244 (21.6) 1137 (14.9)
Not Hispanic or Latino 5613 (86.3) 885 (78.2) 6498 (85.1)
Race
White 4961 (76.3) 814 (72.0) 5775 (75.6)
Asian 649 (10.0) 127 (11.2) 776 (10.2)
Black 690 (10.6) 142 (12.6) 832 (10.9)
Other 206 (3.2) 48 (4.2) 254 (3.3)
Weight (kg) 96.8 ± 22.8 92.3 (22.9) 96.1 ± 22.9
BMI (kg/m2) 33.7 ± 6.9 33.1 (6.8) 33.6 ± 6.9
Hyperlipidemia 5517 (84.8) 803 (71.0) 6320 (82.8)
Smoking
Current 734 (11.3) 118 (10.4) 852 (11.2)
Previous 2937 (45.1) 416 (36.8) 3353 (43.9)
Prior myocardial infarction 2601 (40.0) – 2601 (34.1)
Heart failure 947 (14.6) – 947 (12.4)
Cerebrovascular disease 1236 (19.0) – 1236 (16.2)
Diabetes duration (y) 16.1 ± 8.9 15.2 ± 8.2 16.0 ± 8.8
HbA1c (%) 8.4 ± 1.6 8.6 ± 1.7 8.4 ± 1.7
Oral agents
1 oral agent 2647 (40.7) 508 (45.0) 3155 (41.3)
2 oral agents 1482 (22.8) 359 (31.8) 1841 (24.1)
3+ oral agents 346 (5.3) 68 (6.0) 414 (5.4)
GLP-1 RA treatment 521 (8.0) 78 (6.9) 599 (7.8)
Insulin naïve 950 (14.6) 236 (20.9) 1186 (15.5)
Insulin treated
Premix 639 (9.8) 97 (8.6) 736 (9.6)
Short acting 2510 (38.6) 297 (26.3) 2807 (36.8)
Intermediate acting⁎ 917 (14.1) 196 (17.3) 1113 (14.6)
Long acting 3996 (61.4) 598 (52.9) 4594 (60.2)
eGFR (mL/[min SSA]) 66.3 ± 21.8 76.4 ± 16.6 67.8 ± 21.4
Total cholesterol (mg/dL) 164.1 ± 47.3 170.4 ± 43.1 165.0 ± 46.7
LDL (mg/dL) 84.5 ± 36.7 90.6 ± 35.2 85.4 ± 36.5
HDL (mg/dL) 43.9 ± 12.7 47.4 ± 13.4 44.4 ± 12.9
Triglycerides (mg/dL) 187.2 ± 160.4 166.1 ± 102.4 184.1 ± 153.4
Medications
Aspirin 4229 (65.0) 535 (47.3) 4764 (62.4)
Other anti-platelet medications 1577 (24.2) 22 (1.9) 1599 (20.9)
Statins 5240 (80.5) 732 (64.7) 5972 (78.2)
Other lipid medications 277 (4.3) 71 (6.3) 348 (4.6)
Any HTN medication 6168 (94.8) 1005 (88.9) 7173 (93.9)
β-blockers 4016 (61.7) 354 (31.3) 4370 (57.2)
Calcium channel blockers 2093 (32.2) 367 (32.4) 2460 (32.2)
Renin system blockers 5118 (78.7) 900 (79.6) 6018 (78.8)
Data listed are number (proportion [percentage]) or mean (SD)
Hyperlipidemia was defined as those patients on lipid-modifying agents.
BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist;
HDL, high-density lipoprotein; HTN, hypertension; LDL, low-density lipoprotein; NPH, neutral protamine Hagedorn; SD, standard deviation; SSA, square surface area.
⁎ Intermediate-acting insulin cover human insulin, NPH, and unknown types of insulin. A treatment in the insulin category is included if the patient has initiated the treatment before
randomization.
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and schedules (17%), and current or past malignant
neoplasms (14%). The baseline demographics are shown
in Table II. The majority of patients were male (64.2%)
and Caucasian (76.3%). The mean (SD) age was 65.0 (±
7.4) years with a mean duration of diabetes of 16.0 (±8.8)
years. The mean body mass index was 33.6 (±6.9) kg/m2
and 82.8% had hyperlipidemia (those patients onlipid-modifying agents). The mean HbA1c was 8.4% (±
1.7) at baseline and 41.3% of patients were on oral
monotherapy, 24.1% were receiving oral dual therapy,
and 5.4% were receiving oral triple therapy, whereas only
15.5% were insulin naïve. In terms of CVD, 34.1% had a
history of myocardial infarction, 16.2% had a prior stroke
or TIA, while 12.4% had chronic heart failure (NYHA class
II-III). In addition, 31.2% of the total population had
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patients, 78.2% received lipid-lowering therapy, and
93.9% were treated with antihypertensive agents. The
trial is expected to be completed in Q4 of 2016 and
results will be communicated thereafter.Discussion
Diabetes affects approximately 1 in 11 adults or 415
million people worldwide.7 Approximately 90% of
individuals with diabetes have T2D, which is associated
with a heightened risk of cardiovascular complications
and decreased lifespan.8
T2D is a progressive disorder characterized by a
combination of insulin resistance and diminished insulin
secretion as well as other metabolic abnormalities.
Glycemic control is often suboptimal and many patients
ultimately require treatment with insulin to achieve
optimal glycemic control. The addition of basal insulin
therapy is widely regarded as appropriate for many
patients, whether early or late in the course of the
disease. Given that β-cell function declines as T2D
duration progresses, basal insulin may not be adequate
to control the rise in glucose after meals, so the need for a
basal-bolus strategy may be required. Administration of a
basal insulin with a more stable kinetic profile would
allow a patient to safely target a fasting glucose level by
providing consistent glucose-lowering over a 24-hour
period with a flat pharmacokinetic profile, and decreas-
ing the likely occurrence of hypoglycemia.
Insulin degludec was engineered to achieve improved
pharmacokinetic and pharmacodynamic properties such
as a long duration of action and reduced intrapatient
variability.9,10 There is a single amino acid deletion of
threonine at B30 and a dicarboxylic fatty acid addition to
lysine at position B29. With subcutaneous injection, IDeg
forms soluble, stable multihexamers. Bioactive IDeg
monomers dissociate slowly from the subcutaneous
space and diffuse into the circulation, yielding a duration
of action of approximately 40 hours.11 In several phase 3
clinical trials, IDeg was noninferior to insulin comparators
in reducing HbA1c in insulin-naïve T2D, insulin-treated
T2D, and type 1 diabetes patients.12-14 The observed
reductions inHbA1c range from1.1% to 1.6%with IDeg and
1.2% to 1.4% reduction with the insulin comparator arm
during the first 12 to 16 weeks. Glycemic control persisted
through 52 weeks of follow-up, with an end-of-trial HbA1c
that approximated 7% in the T2D basal-only therapy
trials.15-18 A meta-analysis of the phase 3 trials demon-
strated that treatment with IDeg is associated with a lower
risk of hypoglycemia, particularly nocturnal confirmed
hypoglycemia, compared with IGlar at a similar level of
glycemic control. IGlar was selected as the comparator in
DEVOTE as it is the most commonly prescribed insulin
globally and its cardiovascular safety was established in the
ORIGIN clinical trial.19ORIGIN randomly assigned 12,537 people with im-
paired fasting glucose and impaired glucose tolerance or
T2D to either IGlar or standard of care. The primary
outcome included nonfatal myocardial infarction, non-
fatal stroke, or cardiovascular death. At 7 years of
follow-up, there was no difference in the frequency of
the primary end point between the IGlar and
standard-of-care cohorts (HR 1.02 [95% CI, 0.94-1.11]),
nor were there any differences in the components of the
composite between the 2 study groups. ORIGIN also
demonstrated that the early use of basal insulin to
normalize fasting plasma glucose was not associated
with cancer, but was associated with a reduced
frequency in the diagnosis of diabetes and an increased
risk of both hypoglycemia and weight gain.
Conclusion
DEVOTE is a phase 3b, randomized, double-blind,
active comparator-controlled clinical trial that aims to
evaluate the cardiovascular safety of IDeg relative to IGlar
in patients with T2D at a heightened risk of cardiovascular
complications. It is expected that DEVOTE will provide
conclusive data regarding the cardiovascular safety and
efficacy of IDeg. Methodologically, it is the first
double-blind, active-comparator, cardiovascular outcome
trial of a specific antihyperglycemic therapy.
Author contributions
All authors confirm that they meet the International
Committee of Medical Journal Editors uniform require-
ments for authorship. All authors contributed to drafting/
critically revising the article, approval of the final
manuscript and sharing in the final responsibility for the
content of the manuscript and the decision to submit it
for publication.Conflicts of interest for authors
Dr Steven Marso has received personal fees from
Abbott Vascular, Novo Nordisk, University of Oxford,
and Bristol-Myers Squibb; and research support from
Novo Nordisk, The Medicines Company, and Terumo
Medical.
Dr Darren McGuire has received personal fees from
Boehringer-Ingelheim, Janssen Research and Develop-
ment LLC, Sanofi-Aventis Group, Genentech Inc, Merck
Sharp and Dohme, Daiichi Sankyo Inc, Lilly USA, Novo
Nordisk, GlaxoSmithKline, Takeda Pharmaceuticals
North America, Bristol-Myers Squibb, AstraZeneca, Orexi-
gen, Lexicon, Eisai, Regeneron, Janssen, Merck, Pfizer,
and Genfit; personal fees from University of Oxford, Duke
Clinical Research Institute, Partners HealthCare, and the
Cleveland Clinic Foundation; and nonfinancial support
from Gilead Sciences.
182 Marso et al
American Heart Journal
September 2016Prof Bernard Zinman has received grant support from
Boehringer-Ingelheim, AstraZeneca and Novo Nordisk;
and consulting fees from AstraZeneca, Boehringer-Ingel-
heim, Eli Lilly, Janssen, Merck, Novo Nordisk, and Sanofi
Aventis.
Prof Neil Poulter has received personal fees from
Servier, Takeda, and Novo Nordisk in relation to speakers'
fees (concerning diabetes mellitus); and research grants
for his research group (relating to T2D mellitus) from
Diabetes UK, NIHR EME, Julius Clinical, and the British
Heart Foundation.
Dr Scott S. Emerson has received personal fees related
to Data Monitoring Committees from CTIBioPharma,
Arena Pharmaceuticals, SFJ Pharmaceuticals, BioMarin,
Medivation, Biom'up, Dynavax, Genentech, GlaxoS-
mithKline, Janssen Research, Novartis, Pfizer, Roche,
Sarepta, and Xoma; personal fees related to other
statistical consulting from AstraZeneca, Celltrion, Sarepta,
Sprout, Sanofi, Collegium Pharmaceutical, and Intercept;
and research grant support from NHLBI.
Prof Thomas Pieber has received research support from
Novo Nordisk (paid directly to the Medical University of
Graz); personal fees as a consultant from AstraZeneca,
Bristol-Myers Squibb, Eli Lilly, Novo Nordisk, and Roche
Diabetes Care. Prof Pieber is also the CSO of CBmed
(Center for Biomarker Research in Medicine), a pub-
lic-funded research company.
Dr Richard Pratley's services were paid for directly to
Florida Hospital, a nonprofit organization. Sponsor
AstraZeneca paid for the speaker and consultant.
Sponsor Boehringer-Ingelheim paid for the consultant.
SponsorGilead Sciences paid for the research grant. Sponsor
GlaxoSmithKline paid for the consultant. Sponsor Hanmi
Pharmaceutical Co, Ltd paid for the consultant. Sponsor
Lilly paid for the research grant. Sponsor Merck paid for
the research grant and consultant. Novo Nordisk paid for
the research grant, speaker, honoraria, and consultant.
Sponsor Sanofi-Aventis US, LLC paid for the research
grant. Sponsor Takeda paid for the research grant and
consultant.
Martin Lange, Kirstine Brown Frandsen, Poul-Martin
Haahr, and Rasmus Rabøl are full-time employees of and
hold stock in Novo Nordisk A/S.
Dr John Buse reports grant and consultation fees to the
University of North Carolina (UNC) under contract and
travel/meals/lodging for contracted activities from Novo
Nordisk during the conduct of the study; grants and fees
for consultation to UNC under contract and travel/meals/
lodging for contracted activities from Eli Lilly, GI
Dynamics, Amylin, Orexigen, Merck, Novo Nordisk,
Transtech Pharma, AstraZeneca, Takeda, Sanofi, and
Lexicon; fees for consultation to UNC under contract
and travel/meals/lodging for contracted activities from
Hoffmann-La Roche, Bristol-Myers Squibb, Liposcience,
Elcelyx, Metavention, Dance Biopharm Inc, and Quest;
grants from Medtronic Minimed, Tolerex, Osiris, Halo-zyme, Pfizer, Johnson & Johnson, Andromeda, Boehrin-
ger-Ingelheim, GlaxoSmithKline, Astellas, MacroGenics,
Intarcia Therapeutics, and Scion NeuroStim; stock
options in PhaseBio outside the submitted work; and is
or has been a member of a variety of nonprofit boards:
American Diabetes Association, DiabetesSisters, Taking
Control of Your Diabetes, AstraZeneca Healthcare
Foundation, Bristol-Myers Squib Together on Diabetes
Foundation, and the National Diabetes Education
Program.Acknowledgements
This trial was sponsored by Novo Nordisk (Bagsvaerd,
Denmark). We thank the trial investigators, trial staff,
and trial participants for their participation and
Watermeadow Medical (sponsored by Novo Nordisk)
for providing submission support.References
1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of
hyperglycemia in type 2 diabetes, 2015: a patient-centered
approach: update to a position statement of the American Diabetes
Association and the European Association for the Study of Diabetes.
Diabetes Care 2015;38:140-9.
2. FDA Briefing Document. Insulin degludec and insulin degludec/insulin
aspart treatment to improve glycemic control in patients with diabetes
mellitus briefing document. 2012. [Available at: http://www.fda.gov/
downloads/AdvisoryCommittees/CommitteesMeetingMaterials/
Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/
UCM327017.pdf; last accessed 31 March 2016].
3. World Medical Association. Declaration of Helsinki. Ethical principles for
medical research involving human subjects. J Indian Med Assoc
2009;107:403-5.
4. ICH Harmonised Tripartite Guideline: guideline for good clinical
practice. J Postgrad Med 2001;47:199-203.
5. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate
glomerular filtration rate. Ann Intern Med 2009;150:604-12.
6. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes:
a report of a workgroup of the American Diabetes Association and the
Endocrine Society. Diabetes Care 2013;36:1384-95.
7. Federation ID. IDF diabetes atlas. 7th ed. Brussels, Belgium: International
Diabetes Federation. 2015. [Available at: http://www.diabetesatlas.
org/resources/2015-atlas.html; last accessed 31 March 2016].
8. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke
statistics—2015 update: a report from the American Heart Association.
Circulation 2015;131:e29-322.
9. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel
protraction mechanism of insulin degludec, an ultra-long-acting basal
insulin. Pharm Res 2012;29:2104-14.
10. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower
pharmacodynamic variability than insulin glargine under steady-state
conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-64.
11. Haahr H, Heise T. A review of the pharmacological properties of
insulin degludec and their clinical relevance. Clin Pharmacokinet
2014;53:787-800.
12. Vora J, Cariou B, Evans M, et al. Clinical use of insulin degludec.
Diabetes Res Clin Pract 2015;109:19-31.
Marso et al 183
American Heart Journal
Volume 17913. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal
insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin
aspart in type 1diabetes (BEGINBasal-Bolus Type 1): a phase 3, randomised,
open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1489-97.
14. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an
ultra-longacting basal insulin, versus insulin glargine in basal-bolus
treatment with mealtime insulin aspart in type 2 diabetes (BEGIN
Basal-Bolus Type 2): a phase 3, randomised, open-label,
treat-to-target non-inferiority trial. Lancet 2012;379:1498-507.
15. Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of
insulin degludec given in variable once-daily dosing intervals
compared with insulin glargine and insulin degludec dosed at the
same time daily: a 26-week, randomized, open-label,
parallel-group, treat-to-target trial in individuals with type 2
diabetes. Diabetes Care 2013;36:858-64.16. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus
insulin glargine in insulin-naive patients with type 2 diabetes: a
1-year, randomized, treat-to-target trial (BEGIN Once Long).
Diabetes Care 2012;35:2464-71.
17. Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200
units/ml once daily improves glycemic control similarly to insulin glargine
with a low risk of hypoglycemia in insulin-naive patients with type 2
diabetes: a26-week, randomized, controlled,multinational, treat-to-target
trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013;36:2536-42.
18. Philis-Tsimikas A, Del Prato S, Satman I, et al. Effect of insulin degludec
versus sitagliptin in patients with type 2 diabetes uncontrolled on oral
antidiabetic agents. Diabetes Obes Metab 2013;15:760-6.
19. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin
and cardiovascular and other outcomes in dysglycemia. N Engl J Med
2012;367:319-28.
